Classification
Compound class	Synthetic organic
Approved drug?	Yes (FDA (2015), EMA (2017), Japan (unknown))

IUPAC Name

9-ethyl-6,6-dimethyl-8-(4-morpholin-4-ylpiperidin-1-yl)-11-oxo-5H-benzo[b]carbazole-3-carbonitrile

International Nonproprietary Names
INN number	INN
9699	alectinib

Synonyms

AF802 | Alecensa® | CH5424802

Comments

Alectinib is a second generation ALK inhibitor. It was developed to inhibit the expression of the mutated ALK gene that causes growth of some non-small cell lung cancers, in patients whose cancer has become resistant to the older ALK inhibitor, crizotinib [2,5]. However, additional mutations may develop which confer alecitinib resistance [1]. Cells harbouring these novel mutations are reported to be sensitive to ceritinib and other next-generation ALK tyrosine kinase inhibitors [1]. The identification of the mechanisms by which acquired tumour resistance occurs highlights the importance of being able to use the correct drug for the correct patient to maximise the clinical benefit [4] The design and synthesis of alectinib (CH5424802) is described in [2].

Database Links
CAS Registry No.	1256580-46-7
ChEMBL Ligand	CHEMBL1738797
GtoPdb PubChem SID	223366072
PubChem CID	49806720
RCSB PDB Ligand	EMH
Search Google for chemical match using the InChIKey	KDGFLJKFZUIJMX-UHFFFAOYSA-N
Search Google for chemicals with the same backbone	KDGFLJKFZUIJMX
Search PubMed clinical trials	alectinib
Search PubMed titles	alectinib
Search PubMed titles/abstracts	alectinib
Search UniChem for chemical match using the InChIKey	KDGFLJKFZUIJMX-UHFFFAOYSA-N
Search UniChem for chemicals with the same backbone	KDGFLJKFZUIJMX